Highlights
• Artrya gained 0.84% to $4.215 on 4 September 2026
• FY26 statutory Revenue of A$28,000 following an accounting adjustment to A$177,000
• Net loss after tax increased to A$25.183 million from A$16.406 million in FY25
• Cash and investments stood at A$74.0 million at 30 June 2026
Artrya Ltd (ASX:AYA) edged higher by 0.84% to $4.215 on 4 September 2026. The Perth-based artificial intelligence coronary imaging company continues to attract investor interest despite reporting a widening net loss in FY26, underpinned by a solid cash reserve that provides meaningful runway for clinical and commercial development.
About the Company
Artrya is an Australian health technology company that has developed Salix — an AI-powered software platform for automated analysis of coronary computed tomography angiography (CCTA) scans. Salix is designed to help cardiologists and radiologists rapidly and accurately assess coronary artery disease, reducing the time and variability associated with manual image interpretation. Artrya has received regulatory clearances in the United States, Australia and Europe and is focused on commercial deployment in cardiology centres and hospital imaging departments.
Key Developments
For FY26, Artrya reported statutory revenue of A$28,000, following a A$149,000 accounting adjustment to A$177,000 of revenue. Net loss after tax increased to A$25.183 million, from A$16.406 million in FY25. Cash and investments stood at A$74.0 million at 30 June 2026, including A$44.0 million cash, with nil debt.
Key Catalysts to Watch
• Commercial uptake of Salix in US and Australian cardiology markets
• Expansion of hospital and health system agreements for AI imaging software
• Clinical evidence publications supporting Salix's diagnostic accuracy
• Any Partnership or integration deals with major radiology or cardiology platforms
Risks
• Very early-stage revenue (A$28,000 in FY26) relative to operating costs
• Widening net loss as R&D and commercial spending increases
• AI imaging is a competitive and fast-evolving field
• Cash burn will eventually require additional Capital raising
Conclusion
Artrya is an early-stage health technology company with an AI product that addresses a genuine unmet need in cardiac imaging. However, FY26 revenue of A$28,000 against a A$25 million net loss illustrates the significant distance between the company's current position and commercial viability. The A$74 million cash reserve provides breathing room. Investors considering AYA should be aware this is a high-conviction, long-horizon bet on AI cardiology adoption, with binary risks attached.






Please wait processing your request...